Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naïve Genotype 1b Chronic Hepatitis C Patients
Joint Authors
Ide, Tatsuya
Kato, Keizo
Atsukawa, Masanori
Tsubota, Akihito
Abe, Hiroshi
Chuganji, Yoshimichi
Toyoda, Hidenori
Sata, Michio
Asano, Toru
Takaguchi, Koichi
Kumada, Takashi
Sakamoto, Choitsu
Shimada, Noritomo
Aizawa, Yoshio
Source
Gastroenterology Research and Practice
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-12, 12 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-08-14
Country of Publication
Egypt
No. of Pages
12
Main Subjects
Abstract EN
We evaluated the genetic variation in rs8099917, substitutions in core amino acid (aa) 70, and the number of aa substitutions in the interferon sensitivity-determining region (ISDR) on the prediction of sustained virological response (SVR) in treatment-naïve hepatitis C virus (HCV) genotype 1b (G1b) patients.
This multicenter study involved 150 Asian treatment-naïve patients infected with HCV G1b who received 12 weeks of telaprevir in combination with 24 weeks of peginterferon-α-2b and ribavirin.
The baseline and treatment-related factors potentially associated with SVR were determined by multivariate logistic regression analysis.
Virological response was analyzed on an intent-to-treat basis.
Cessation of the therapy due to adverse effects occurred in only 2 patients, who discontinued the trial at 10 weeks and at 2 weeks due to cerebral infarction and renal impairment, respectively.
Among the 150 patients in whom the final virological response was determined, only genotype TT in rs8099917 was identified as a pretreatment predictor (P = 7.38 × 10−4).
Achievement of a rapid virological response (RVR), defined as undetectable HCV RNA at week 4 of treatment, was identified as an after-starting-treatment predictor (P = 2.47 × 10−5).
However, neither a substitution in core aa 70 nor the number of substitutions in the ISDR affected treatment outcome.
American Psychological Association (APA)
Abe, Hiroshi& Tsubota, Akihito& Shimada, Noritomo& Atsukawa, Masanori& Kato, Keizo& Takaguchi, Koichi…[et al.]. 2014. Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naïve Genotype 1b Chronic Hepatitis C Patients. Gastroenterology Research and Practice،Vol. 2014, no. 2014, pp.1-12.
https://search.emarefa.net/detail/BIM-480697
Modern Language Association (MLA)
Abe, Hiroshi…[et al.]. Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naïve Genotype 1b Chronic Hepatitis C Patients. Gastroenterology Research and Practice No. 2014 (2014), pp.1-12.
https://search.emarefa.net/detail/BIM-480697
American Medical Association (AMA)
Abe, Hiroshi& Tsubota, Akihito& Shimada, Noritomo& Atsukawa, Masanori& Kato, Keizo& Takaguchi, Koichi…[et al.]. Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naïve Genotype 1b Chronic Hepatitis C Patients. Gastroenterology Research and Practice. 2014. Vol. 2014, no. 2014, pp.1-12.
https://search.emarefa.net/detail/BIM-480697
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-480697